Triple-negative breast cancers lack the presence of the estrogen receptor, progesterone receptor, and HER2/NEU protein. This subtype of breast cancer can be aggressive, difficult to treat, and more likely to recur than other subtypes of breast cancer. Obesity can increase the risk of breast cancer by causing breast inflammation, which has been linked to cancer. The purpose of this study is to see if treatment with docosahexaenoic acid (DHA) in overweight and obese survivors of triple-negative breast cancer for six months reduces the amount of inflammation in the breast. If the effects are significant, it might be possible to use DHA to reduce the risk of breast cancer development and recurrence.
DHA is a fatty acid that is present in some foods (such as fatty fish) and in fish oil supplements. DHA is known to inhibit cancer-fueling chemicals produced by certain immune cells that accumulate in inflamed breast tissue. It is not yet known if DHA can reduce the risk of breast cancer.
Participants in this study will be randomly assigned to receive either DHA capsules or placebo (sugar) capsules. Researchers will compare the levels of certain “biomarkers” of inflammation in the blood and breast tissue in both groups.